Luis Mora Capitán
Managing Director, Oncology Business Unit

Luis Mora began his career as the Financial Controller for Zambon, S.A. and Pharmazam, S.A. in Barcelona and later as Head of Finance for Zambón Portugal. From 1995-2000 he served as Financial Controller with the Antibióticos Group (Montedison), and as Board Member of Vitatene, in Milan, Italy.

He joined PharmaMar in 2000 as Chief Financial Officer and was appointed Managing Director in 2008.

Heiner Pieper
VP, Business Development & Licensing

Heiner graduated in Economics and Business Administration at the University of Cologne, Germany and started his industrial career in pharma at Bayer. Heiner Pieper holds more than 20 years of expience in commercial functions in Europe and Latin America, and has also worked for ASTA Medica AG and Baxter Oncology GmbH in Frankfurt, among others, as country manager in Argentina as well as regional director for Latin America where he led the Oncology operations for key brands such as Navelbine® and Holoxan®. In 2003, he joined Merck KGaA’s headquarters in Darmstadt, Germany, where he took over the role of regional director Latin America and launched the monoclonal antibody Erbitux® within the Oncology franchise.

With the acquisition of Serono in 2007 he moved to business development and headed MerckSerono’s Global BD&L department for emerging markets and general medicine before joining PharmaMar in May 2013 as VP, Business Development and Licensing.

He is a member of the Pharmaceutical Licensing Club in Germany (PLCD) and part of the European network of Pharmaceutical Licensing groups (EPLG).

Carmen Cuevas Marchante, Ph.D.
Director, Research & Development

Carmen joined PharmaMar in 1997 performing in different positions in the R&D Department. In 2003, she was appointed Director of Research & Development at PharmaMar, where she is responsible for the areas of drug discovery, medicinal chemistry and preclinical. Carmen has authored more than 85 scientific publications in specialized journals and has been invited to speak numerous times at international scientific congresses and research institutions. She has an impressive record in the drug discovery space with about 21 patent applications and more than 20 funded research programs. Among other achievements, she is responsible for the development of the innovative synthesis process of the marine-derived anticancer drug, YONDELIS®.

Carmen obtained her Ph.D. in Chemistry from the University of the Basque Country, and completed her post-doctoral training at the School of Medicine of University of Alcala de Henares in Madrid working within the Pharmacology Department. She also obtained a management development program diploma from IESE.

Juan Nogués Ortuño
Director, International Marketing and Sales

Juan obtained his degree in Law and Business Administration (ICADE E-3) at the Comillas Pontifical University and a master degree (PADE) from IESE Business School. He has over 30 years of experience in the pharmaceutical sector. Since 1983, Juan has held various positions in the commercial department of the Spanish subsidiaries of Roche (Medical Representative and Product Manager), CECA (Product Manager), Glaxo (Marketing and Market Research Manager), GlaxoWellcome (Marketing Director), GSK (Hospitals and Oncology Business Unit Director) and Eisai (Managing Director).

He joined PharmaMar in 2012 as International Sales Associate Director, and in February 2013 was appointed to his current position as International Marketing and Sales Director.

Luis Rupérez Cuenca
Director, Human Resources and IT

Luis obtained his graduate degree in Psychology from the Complutense University of Madrid, complementing his background with a Marketing and Sales Management Program and a Human Resources Management Program.

Since 1992, he has been working in the Pharmaceutical Industry where he has held responsible positions as Human Resources Director for companies such as Servier Laboratories in Paris (France) and Antibióticos Farma. Before that, he has also worked in the area of Human Resources in companies of the service industry, such as Ibermática and Sofemasa (Sema Group). He joined PharmaMar in 2003 as Human Resources Director.

Elena Calleja Crespo
Director, Finance Oncology Business Unit

Elena obtained her degree in economics, with a focus on the Public Sector and Monetary Economy, from the Complutense University of Madrid and a masters in Corporate Tax Consultancy from ICADE University.

She started her professional career at PriceWaterhouse in Madrid in the Audit division and then moved to the Tax, Legal and Financial Division, where she worked until 1994. She was Senior Consultant in C&G, where she managed tax consultancy and financial projects in various companies, both public and private, within the logistics, transport and technological research sectors. In 1998, she returned to PricewaterhouseCoopers Madrid as Consultant within the Tax, Legal and Financial Division to various global financial sector clients.

She joined PharmaMar in 2002 as Financial Controller., a position she held until she was appointed Finance Director in April 2008.

Alfonso Ortín
Director, Communications

Electrical Engineer by profession, Alfonso started to accumulate experience setting up the Press Office of Mercedes- Benz Spain, to, for the last 28 years lead the Communications Department at FCA. Expert in Strategy Definition and Crisis Management, he began work in his current position at PhamaMar in 2016.

Pascal Besman
Chief Operating Officer of PharmaMar U.S.

Pascal Besman is the Chief Operating Officer working for PharmaMar in the United States, overseeing the implementation of PharmaMar’s operational infrastructure in the United States. Mr. Besman joins PharmaMar from Maxim Group, a New York-based global investment bank, where he served as Head of Healthcare Equity Sales since 2014. In addition to Maxim Group, Mr. Besman served as a health care specialist and institutional equity salesperson at several leading investment banks, including JMP Securities, UBS, Bear Stearns, Lehman Brothers and Merrill Lynch. He authored for many years a widely-read weekly biotech overview newsletter for C-suite executives entitled The Buzz. Mr. Besman holds a B.Sc. from the London School of Economics.

Ali Zeaiter, M.D.
Director, Clinical Development

Ali Zeaiter has recently joined PharmaMar as the Director of Clinical Development in our Oncology Business Unit. Ali Zeaiter is a board certified Medical Oncologist with over 13 years experience in the pharmaceutical industry. Before joining PharmaMar, Ali was the Head of Clinical Development of the Onco-haematology therapeutic area at Servier Laboratories in Paris between March and September 2018, where he led the integration of Shire Oncology within the French Group starting from April 2018. Before working at Servier, he spent 11 years of his career at F. Hoffmann-La Roche AG in Basel, Switzerland (between 2007 and 2018). In his role as Global Development Team Leader at Roche, Ali led the development strategies of different projects such as Avastin (in lung cancer, Pediatric and Glioblastoma), Tarceva and Alecensa, and was member of the Lung Disease Area Strategy (LDAS) of the company. Before joining Roche, between 2003 and 2007 Ali served as Medical Oncologist in different hospitals of Paris and in parallel worked 2 years at the oncology-specialized CRO Cvitkovic et Associés Consultants.

Maria Jose Arce-Tomas, PhD
Global Head of Regulatory Affairs

María joined PharmaMar from Novo Nordisk A/S where she was the Corporate Global Vice President and Head of Biopharm Global Regulatory Affairs.

Prior to Novo Nordisk, María held a number of senior corporate leadership positions at GE Healthcare, GSK, Abbott, Takeda and Norgine. In these roles, she was instrumental in leading and setting the strategic direction of her organisation, leading the development, registration and successful marketing of a number of company's key assets. She has extensive R&D and regulatory experience in biologics and small molecules in several therapeutic areas and a record of developing and leading high performing teams.

María holds a PhD in Biochemistry from King’s College, University of London, an MSc in Toxicology and a BSc in Pharmacy from Valencia University in Spain. She also has a Postgraduate Diploma in Regulatory Affairs from the University of Cardiff.

Carmen Eibe
Director, Project Coordination

Graduated in Economics and Business Administration from the University of Seville and Executive MBA from the School of Business Administration (EAE), she joined the Zeltia Group in 2003 where she directs the Department of Project Coordination that manages numerous R+D+I projects in which the group's subsidiaries participate. Recently she was an executive member of the Board of EuropaBio, of the European Biopharmaceutical Enterprises (EBE-EFPIA) and Vicepresident at the Spanish Biotechnology Association (ASEBIO) representing PharmaMar. Previously, since 1998 she was General Secretary of the Chamber of Commerce of Spain in Belgium and Luxembourg, having climbed since 1994 various positions in the institution within the Commercial Department. Meanwhile, during her tenure as head of the Chamber in Brussels, she was appointed General Secretary of the Federation of Spanish Chambers in Europe (FEDECOM).

Shareholders and Investors

Financial Information of the Company, stock information, official notices to the CNMV (Spanish Securities & Exchange Commission), product portfolio and other information.

Newsroom

If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.